These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 7086705

  • 1. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
    [Abstract] [Full Text] [Related]

  • 2. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
    Le Breton GC, Lipowski JP, Feinberg H, Venton DL, Ho T, Wu KK.
    J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
    [Abstract] [Full Text] [Related]

  • 6. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE, Kochel PJ, Saussy DL, Halushka PV.
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [Abstract] [Full Text] [Related]

  • 7. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB, Patscheke H.
    Prog Clin Biol Res; 1989 Aug; 301():315-9. PubMed ID: 2798452
    [Abstract] [Full Text] [Related]

  • 8. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
    Mais DE, Burch RM, Saussy DL, Kochel PJ, Halushka PV.
    J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway.
    Dangelmaier C, Jin J, Smith JB, Kunapuli SP.
    Thromb Haemost; 2001 Feb; 85(2):341-8. PubMed ID: 11246558
    [Abstract] [Full Text] [Related]

  • 10. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

  • 11. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.
    Le Breton GC, Venton DL, Enke SE, Halushka PV.
    Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066
    [Abstract] [Full Text] [Related]

  • 12. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R, Mezzasoma AM, Venditti G, Gresele P.
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [Abstract] [Full Text] [Related]

  • 13. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K, Halushka PV, Yan YT, Wong PY.
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [Abstract] [Full Text] [Related]

  • 14. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA, Batey AJ, Coker SJ.
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [Abstract] [Full Text] [Related]

  • 15. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH, Nichols R, Schmeling JW, Ramwell PW.
    Thromb Res; 1981 Sep 15; 23(6):521-32. PubMed ID: 6798707
    [No Abstract] [Full Text] [Related]

  • 16. [Thrombocyte interaction with a collagen substrate: the role of thrombocyte-synthesized prostaglandin endoperoxides and thromboxane A2].
    Mazurov AB, Leĭtin VL, Repin VS.
    Biull Eksp Biol Med; 1984 Nov 15; 98(11):563-6. PubMed ID: 6439262
    [Abstract] [Full Text] [Related]

  • 17. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
    Turini ME, Holub BJ.
    Biochim Biophys Acta; 1994 Jun 23; 1213(1):21-6. PubMed ID: 8011675
    [Abstract] [Full Text] [Related]

  • 18. Fibrinogen binding is independent of an increase in intracellular calcium concentration in thrombin degranulated platelets.
    Pulcinelli FM, Daniel JL, Riondino S, Gazzaniga PP, Salganicoff L.
    Thromb Haemost; 1995 Feb 23; 73(2):304-8. PubMed ID: 7792747
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
    Patscheke H, Stegmeier K.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Feb 23; 13():371-3. PubMed ID: 3159225
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.